Bitcoin’s EMA Cross Triggers Market Flashback
A rare signal, dreaded by traders, has resurfaced on the bitcoin chart. For the first time since 2022, the asset crosses a critical technical zone, reviving the memory of a prolonged bear market. This moving average crossover, often associated with lasting reversals, fuels concerns of an already seen scenario. While post-halving euphoria struggles to convince, this return to a forgotten configuration could well mark an unexpected turning point in the current BTC cycle.
In brief
- Bitcoin sends a rare technical signal, last observed in 2022, via a weekly moving average crossover.
- This crossover is often associated with a lasting bearish reversal, as in the previous cycle that led BTC to $15,600.
- Analysts question the relevance of the four-year cycle, as the current dynamic suggests a classic bearish scenario.
- The Bitcoin/silver ratio returns to levels seen after the FTX collapse, triggering strong reactions among some traders.
The bearish crossover signal : a return to 2022 market patterns
For the first time since April 2022, the 21-week exponential moving average (EMA) of bitcoin has crossed below its 50-week counterpart, while crypto is already falling amid declining risk appetite.
This technical event, closely followed by analysts, was confirmed by Rekt Capital who stated this Monday on X : “the bullish market exponential moving averages of Bitcoin have officially crossed”.
This crossover is seen as a trend reversal indicator and, historically, it has often marked the start of prolonged consolidation phases. During the previous similar crossover, which occurred in Q2 2022, bitcoin took about seven months to form a bottom at $15,600 in November of the same year.
This technical setup fuels discussions about the current cycle structure. While some observers still challenge the validity of the four-year model, several analysts see it as an almost mechanical repetition of a previously experienced bearish scenario. The following elements were noted in this analysis:
- The 21W EMA has crossed below the 50W EMA : a signal identical to that of the 2022 bear market ;
- The history of the previous crossover : 7 months of decline before reaching a significant low ;
- The current consolidation zone : BTC oscillates around $65,000, with no confirmation of a bullish recovery ;
- A dominant technical reading: several analysts mention “a classic bear market setup”, suggesting a gradual weakening rather than a brutal crash.
The Bitcoin/silver ratio : a return to post-FTX levels
Another worrying signal comes from the behavior of bitcoin against precious metals, particularly silver.
Analyst Daan Crypto Trades pointed out that the BTC/Silver ratio has returned to its end-2022 levels, a period marked by the collapse of the FTX platform. “Bitcoin is currently trading against silver at levels equivalent to those observed during the FTX collapse” he commented on X, calling this observation “amazing”. The chart, shared with his followers, shows that silver reached this level in half the time of bitcoin, despite a general upward trend against the dollar.
This performance asymmetry raises questions about the current perception of risk and the hierarchy of assets considered safe havens. Although both assets have experienced nominal value appreciation, their relative evolution reflects a market shift in interest toward tangible assets.
Daan’s post concludes : “which clearly shows the real reason for these movements: the depreciation of fiat currencies”. This remark reveals growing concerns about monetary depreciation and suggests that BTC’s relative performance could now be influenced by macroeconomic arbitrages rather than dynamics inherent to crypto.
While technical signals recall the dark days of 2022, Bitcoin investor sentiment drops due to US government shutdown fears. Between macroeconomic tensions and bearish indicators, the market remains poised awaiting confirmation or denial of a new retracement cycle.
Maximize your Cointribune experience with our "Read to Earn" program! For every article you read, earn points and access exclusive rewards. Sign up now and start earning benefits.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify
In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
